Lainson John C, Daly Seth M, Triplett Kathleen, Johnston Stephen Albert, Hall Pamela R, Diehnelt Chris W
Biodesign Institute Center for Innovations in Medicine, Arizona State University, Tempe, Arizona 85281, United States.
University of New Mexico College of Pharmacy, Albuquerque, New Mexico 87131, United States.
ACS Med Chem Lett. 2017 Jul 7;8(8):853-857. doi: 10.1021/acsmedchemlett.7b00200. eCollection 2017 Aug 10.
One proposed solution to the crisis of antimicrobial resistant (AMR) infections is the development of molecules that potentiate the activity of antibiotics for AMR bacteria, such as methicillin-resistant (MRSA). Rather than develop broad spectrum compounds, we developed a peptide that could potentiate the activity of a narrow spectrum antibiotic, oxacillin. In this way, the combination treatment could narrowly target the resistant pathogen and limit impact on host flora. We developed a peptide, , composed of a binding peptide and a inhibitory peptide conjugated to a branched peptide scaffold, which has modest activity against but exhibits synergy with oxacillin for MRSA both and in a MRSA skin infection model. The low concentration of and sub-MIC concentration of oxacillin necessary for activity suggest that this molecule is a candidate for future medicinal chemistry optimization.
一种针对抗菌药物耐药性(AMR)感染危机提出的解决方案是开发能够增强抗生素对AMR细菌(如耐甲氧西林金黄色葡萄球菌(MRSA))活性的分子。我们没有开发广谱化合物,而是开发了一种能够增强窄谱抗生素苯唑西林活性的肽。通过这种方式,联合治疗可以精准靶向耐药病原体,并限制对宿主菌群的影响。我们开发了一种肽,由一个结合肽和一个与分支肽支架缀合的抑制肽组成,它对[具体细菌名称未给出]活性较弱,但在体外和MRSA皮肤感染模型中与苯唑西林对MRSA均表现出协同作用。该肽发挥活性所需的低浓度以及苯唑西林的亚抑菌浓度表明,这种分子是未来药物化学优化的一个候选物。